Italy to introduce price cuts and tendering
This article was originally published in Scrip
Executive Summary
The Italian government says that in a bid to cut its drugs bill by €1.2 billion it will introduce price cuts on off-patent medicines and a tendering system that would affect off-patent and generic medicines. The latter could endanger European production of pharmaceuticals, warns Farmindustria, Italy's pharmaceutical industry association.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.